Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biohaven Pays $105m For Turbo Boost In Migraine Drug Review Race

Mar 20 2019

• By Eleanor Malone

Rocket

Related Content

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA's Gottlieb

Jan 09 2019

Related Companies

Biohaven Pharmaceutical Holding Company Ltd.

Allergan plc

Eli Lilly and Company

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

GW Pharmaceuticals plc

Regeneron Pharmaceuticals, Inc.

Sanofi

BioMarin Pharmaceutical Inc.

AbbVie Inc.

United Therapeutics Corporation

Novo Nordisk A/S

SIGA Technologies, Inc

Additional Topics

Drug Review Deals Market Intelligence Commercial Review Pathway Strategy Neurology BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.